Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM